"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has ...

Opens in a new tab or window While high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT) can deepen ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

Researchers sought to better understand the experiences of patients living with multiple myeloma and their perceptions of palliative care.

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Brian Griffin has incurable blood cancer and, while he is well enough at the moment after a second and final stem cell ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...